Literature DB >> 20440539

Tonsillar pseudotumor: complications of chronically-administered temozolomide.

Kathleen Grisdale1, Melesa Ritterhouse, Kathy Hunter, Michelle D Williams, Morris D Groves.   

Abstract

The current standard of care for patients with Glioblastoma multiforme (GBM) is surgery, followed by radiation in combination with Temozolomide (TMZ), followed by adjuvant TMZ. The most appropriate length of treatment of adjuvant TMZ after the completion of radiation is unclear. We present the case of a 45 year old female with GBM who received adjuvant TMZ on an experimental study for 24 1-month cycles (150 mg/M(2) 7 days on/7 days off continuously-a higher TMZ dose than standard). After 24 months on study she was stable without GBM regrowth, but presented with a right tonsil and pharynx mass consistent with a new primary malignancy. Tonsillar biopsy was positive for Epstein-Barr virus, Cytomegalovirus and Herpes Simplex Virus, but no tumor. This case highlights the risks and possible complications of immunosuppression associated with long term TMZ use.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20440539     DOI: 10.1007/s11060-010-0207-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  11 in total

Review 1.  Antiviral therapy of herpes simplex.

Authors:  R Snoeck
Journal:  Int J Antimicrob Agents       Date:  2000-10       Impact factor: 5.283

Review 2.  The lung in the immunocompromised patient. Infectious complications part 2.

Authors:  M Tamm
Journal:  Respiration       Date:  1999       Impact factor: 3.580

3.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

Authors:  W K Yung; M D Prados; R Yaya-Tur; S S Rosenfeld; M Brada; H S Friedman; R Albright; J Olson; S M Chang; A M O'Neill; A H Friedman; J Bruner; N Yue; M Dugan; S Zaknoen; V A Levin
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

4.  The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.

Authors:  David E Gerber; Stuart A Grossman; Michel Zeltzman; Michele A Parisi; Lawrence Kleinberg
Journal:  Neuro Oncol       Date:  2006-11-15       Impact factor: 12.300

5.  Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.

Authors:  P Hau; D Koch; T Hundsberger; E Marg; B Bauer; R Rudolph; M Rauch; A Brenner; P Rieckmann; J Schuth; T Jauch; H Koch; U Bogdahn
Journal:  Neurology       Date:  2007-02-27       Impact factor: 9.910

6.  Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.

Authors:  Y B Su; Sejean Sohn; Susan E Krown; Philip O Livingston; Jedd D Wolchok; Carolyn Quinn; Linda Williams; Theresa Foster; Kent A Sepkowitz; Paul B Chapman
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

8.  Disseminated salmonellosis in a patient treated with temozolomide.

Authors:  Georgiana Georgescu; Ignatio M Isola; Souad Youssef; Javier Adachi; Kenneth Rolston
Journal:  J Infect       Date:  2008-08-19       Impact factor: 6.072

9.  Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.

Authors:  James R Perry; Philippe Rizek; Rosemary Cashman; Meredith Morrison; Tara Morrison
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

10.  Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology?

Authors:  E Binello; I M Germano
Journal:  J Neurooncol       Date:  2009-02-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.